Aclarion Sets Pricing for $14.4 Million Public Offering, Combining Stock and Warrants
Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company utilizing biomarkers and proprietary augmented intelligence algorithms to aid in the diagnosis of chronic low back pain, has announced the pricing details for its underwritten public offering. The offering comprises approximately 144 million shares of common stock or pre-funded warrants, each unit paired with both a Series A and Series B common warrant.

Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company utilizing biomarkers and proprietary augmented intelligence algorithms to aid in the diagnosis of chronic low back pain, has announced the pricing details for its underwritten public offering. The offering comprises approximately 144 million shares of common stock or pre-funded warrants, each unit paired with both a Series A and Series B common warrant.
According to the pricing structure, each share of common stock or pre-funded warrant is bundled with a Series A warrant and a Series B warrant, both exercisable at $0.20 per share. The combined public offering price for each unit, including the common stock and attached warrants, is set at $0.10, while units with pre-funded warrants are priced slightly lower at $0.09999. Additionally, the company has provided the underwriter with a 45-day option to purchase up to 21 million additional shares of common stock (or pre-funded warrants), along with corresponding Series A and Series B warrants, to address potential over-allotments.
The closing of this offering is anticipated to take place on or around January 16, 2025, subject to customary closing conditions. Dawson James Securities, Inc. is serving as the sole book-running manager for the offering.
Expected Proceeds and Allocation of Funds
The gross proceeds from the offering are projected to reach approximately $14.4 million before deducting underwriting discounts, commissions, and related offering expenses. Aclarion has indicated that the net proceeds will be directed toward the redemption of all outstanding shares of its Series B Preferred Stock. Each share will be redeemed at a price of $1,000, inclusive of accrued but unpaid dividends. The remaining funds will support the enhancement of the company’s product platforms, expansion of its sales and marketing efforts, and general corporate purposes, including administrative expenses.
Offering Details and Legal Disclosures
This public offering is being conducted pursuant to a registration statement on Form S-1 (File No. 333-283724), which was declared effective by the U.S. Securities and Exchange Commission (SEC) on January 14, 2025. Investors can access the official prospectus through the SEC’s website at www.sec.gov or by contacting Dawson James Securities, Inc. at their Boca Raton office. This announcement is not a solicitation to sell or an offer to purchase securities in jurisdictions where such actions would be unlawful.
About Aclarion, Inc.
Aclarion focuses on leveraging advanced technology, including Magnetic Resonance Spectroscopy (MRS), to deliver innovative solutions in healthcare. Its flagship product, Nociscan, is a cloud-based software platform designed to differentiate between painful and non-painful discs in the lumbar spine. By analyzing MRS data, the system identifies biomarkers linked to disc-related pain, providing physicians with critical insights to optimize treatment plans. The solution integrates seamlessly with existing diagnostic tools to improve clinical outcomes for patients with chronic low back pain.
With the completion of this public offering, Aclarion aims to strengthen its position in the healthcare technology sector, further developing its product offerings and market presence.